Glecaprevir/Pibrentasvir Suppliers & Bulk Manufacturers

Available Forms: Oral tablets

Available Strengths: Glecaprevir 100 mg Pibrentasvir 40 mg

Reference Brands: Mavyret®

Category: Hepatitis

Glecaprevir/Pibrentasvir is available in Oral tablets and strengths such as Glecaprevir 100 mg Pibrentasvir 40 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Glecaprevir/Pibrentasvir is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Glecaprevir/Pibrentasvir can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

Glecaprevir/Pibrentasvir is a fixed-dose, pan-genotypic antiviral combination used in the treatment of chronic Hepatitis C virus (HCV) infection across genotypes 1 through 6. Marketed as Mavyret® in the US and EU by AbbVie, it combines Glecaprevir, an NS3/4A protease inhibitor, and Pibrentasvir, an NS5A inhibitor, to deliver a highly effective once-daily oral regimen. Approved by the FDA and EMA, it is indicated for use in adults and pediatric patients (≥3 years), with or without cirrhosis. Glecaprevir/Pibrentasvir is widely used in pharma B2B for short-duration (typically 8–12 weeks) HCV treatment strategies across global markets.